Moderna's cost control continues Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 1 May, 2025

Who are the LGBTQ+ leaders in the industry? Hear insights from the honorees giving voice and visibility to the LGBTQ+ presence in biopharma — join virtually and celebrate with us. Sign up now.

presented by Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

spotlight The Endpoints Slack interview: Arc Institute's Patrick Hsu on investing, AI and new ways of research

news Lilly meets sales expectations, but Novo gains on PBM win Moderna expands effort to rein in costs in an ‘uncertain environment’ Amicus grabs Dimerix’s rare kidney disease drug for $30M upfront Biogen says Leqembi sales are improving slowly following lackluster launch Exclusive: Ex-Calico scientist launches Stately Bio with new way to study cells

VP, Clinical Development / CMO / CDO‬ Autonomy Bio Inc. San Francisco, CA 94107, USA COO / Head of Operations Autonomy Bio Inc. San Francisco, CA 94107, USA ‭ Regulatory Lead / Head of Regulatory‬ Autonomy Bio Inc. San Francisco, CA 94107, USA Research Associate I/II - Gene Therapy MeiraGTx New York, NY, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Exploring Japan as a key market for your drug? Get the roadmap — join senior Japanese leaders to hear firsthand on the regulatory and pricing dynamics behind one of the world’s top pharma markets. Sign up now.

May 12 1:30pm ET How to incorporate pragmatic design elements into your clinical studies sponsored by Flatiron May 29 10:30am ET Optimizing the clinical research workforce - An industry analysis by Parexel sponsored by Parexel

endpoints pharma Exits continue at FDA, as more staff in drug office follow fired colleagues out the door Regeneron loses bid to fend off DOJ fight over Eylea Medicare payments Teladoc buys virtual therapy startup UpLift for $30M BeiGene scores a win from US Patent Office in spat over Brukinsa

in case you missed it 1. Artios drug exploits ‘replication stress’ in cancer, shrinking subset of tumors in early study 2. Updated: Novartis to buy Regulus Therapeutics for up to $1.7B 3.